Beta-hydroxybutyrate

Other Names

(3R)-3-delta-hydroxybutyric acid(3R)-3-hydroxybutanoic acid(R)-(−)-b-Hydroxybutyrate(R)-(−)-beta-hydroxybutyric acid(R)-(−)-β-hydroxybutyric acid(R)-3-hydroxybutanoate(R)-3-hydroxybutanoic acid(R)-3-hydroxybutyric acid(R)-beta-hydroxybutanoic acid(S)-3-hydroxybutanoic acid(S)-3-hydroxybutyric acid(−)-3-hydroxy-n-butyric acid3-(R)-hydroxybutyric acid3-D-hydroxybutyrate3-D-hydroxybutyric acid3-delta-hydroxybutyrate3-hydroxy-butanoic acid3-hydroxybutanoic acid3-HYDROXYBUTANOIC ACID, (R)-3-HYDROXYBUTANOIC ACID, (S)-3-hydroxybutyrate3-hydroxybutyric acid3-OH butyrate3-OH-butyric acid3R-hydroxybutanoic acidb-hydroxy-n-butyrateb-hydroxy-n-butyric acidb-hydroxybutanoateb-hydroxybutanoic acidb-hydroxybutyric acidbeta-D-hydroxybutyric acidbeta-hydroxybutyric acidbetaOHBBHBBHBAButanoic acid, 3-hydroxy-butyrate, 3-hydroxy-butyrate, D-3-hydroxy-butyric acid, 3-hydroxy-D-(−)-(R)-3-hydroxybutyric acidD-3-hydroxybutyrateD-3-hydroxybutyric acidD-beta-hydroxybutyrateD-beta-hydroxybutyric acidD-β-hydroxybutyric aciddelta-3-hydroxybutyratedelta-3-hydroxybutyric aciddelta-beta-hydroxybutyrateDL-3-hydroxybutyric acidDL-beta-hydroxybutyrateDL-β-hydroxybutyric acidketone bodyL-β-hydroxybutyrateNSC-3806R,S-beta-hydroxybutyrateR-beta-hydroxybutyrateS-beta-hydroxybutyrateβ-hydroxy-n-butyrateβ-hydroxy-n-butyric acidβ-hydroxybutanoateβ-hydroxybutanoic acidβ-hydroxybutyric acidβHBβOHB

Synopsis

Beta-Hydroxybutyrate (BHB): A Comprehensive Reference

1. Identity: Chemical Names, Structure, and Natural Origin

Chemical Identity

Beta-hydroxybutyrate, also known as β-hydroxybutyrate, 3-hydroxybutyrate, or βHB, is the deprotonated form of beta-hydroxybutyric acid, which is a hydroxycarboxylic acid having the general formula CH₃CH₂OHCH₂COOH. The deprotonated form present at typical biological pH levels is CH₃CH₂OHCH₂COO⁻.

Although not technically a "ketone," one of skill in the art will recognize that beta-hydroxybutyrate, in the context of ketosis, is commonly referred to as a "ketone body." β-hydroxybutyrate is a reduced form of acetoacetate, in which the ketone group is converted into an alcohol (or hydroxyl) group. Despite this structural distinction, BHB is still considered a ketone body because it is closely related to the other ketone bodies acetoacetate (AcAc) and acetone.

BHB exists as two stereoisomers (enantiomers). The beta-hydroxybutyrate compound can be provided as a racemic mixture of enantiomers (i.e., R,S-beta-hydroxybutyrate, also known as DL-beta-hydroxybutyrate), which can be made synthetically. The R-enantiomer (also designated D-3-hydroxybutyrate) is the biologically active form produced endogenously in mammals. Administering R-beta-hydroxybutyrate, the endogenous form, results in attaining relatively rapid elevated ketosis, while administering S-beta-hydroxybutyrate, which must first be converted to the R form, provides slower and more sustained ketosis.

Common Supplemental Forms and Preparations

Available supplements for inducing ketosis include ketone salts, ketone esters, and medium-chain triglycerides.

BHB mineral salts: BHB mineral salts pair BHB with minerals such as sodium, potassium, calcium, or magnesium. They are common in consumer supplements and usually raise blood BHB more modestly, often in the 0.3 to 0.8 mmol/L range per serving.
Ketone monoesters (KME): Ketone esters are chemically bonded compounds that raise blood BHB quickly and substantially, often into the 1 to 3 mmol/L range within 30 to 60 minutes of a single dose. That magnitude is large enough in many studies to produce measurable acute effects, which is why ketone esters are frequently used in laboratory research.
Free D-BHB acid: A newer form, free D-BHB, is chemically identical to what the body makes, with no added minerals or alcohol precursors. Being salt-free and having no intermediate metabolites or precursors, it could have a broader clinical reach than previous ketone supplements, for example in patients with mineral load restrictions such as those living with heart failure or chronic kidney disease.

The foregoing compounds can be in any desired physical form, such as crystalline, powder, solid, liquid, solution, suspension, or gel.

Natural Endogenous Source

Ketone bodies including beta-hydroxybutyrate, acetoacetate, and acetone are endogenously produced primarily by the liver mitochondria through the breakdown of fatty acids. They are produced as an alternate energy source during periods of carbohydrate abstinence such as fasting, starvation, or ketogenic diets. Beta-hydroxybutyrate is the most abundant and stable ketone body in circulation.

2. Historical and Scientific Background

Discovery

Beta-hydroxybutyrate was first identified in the nineteenth century in the context of diabetic and fasting metabolism. Oskar Minkowski reported on the presence of hydroxybutyric acid (oxybuttersäure) in the urine of patients with diabetes mellitus in 1884. Around the same period, the compound was noted to appear in urine and blood alongside acetoacetate and acetone. Later, Magnus Levy went on to deduce that the increased level of breath acetone present in diabetic or fasting patients was secondary to breakdown of fatty acids and occurred along with production of acetoacetate and beta-hydroxybutyrate, which were measurable in the urine and blood, and the three molecules became an inseparable trio.

Finally, in the 1950s, researchers Kaplan and Lipmann discovered that acetoacetate was the central molecule that underwent chemical change to form acetone or beta-hydroxybutyrate; however, by this time the term "ketone bodies" had stuck and continues to be used today.

Foundational Nutritional Science

An anomaly — the observation that obese subjects who fasted for several weeks survived, despite assumptions that the brain could only use glucose — led to the determination of the metabolic role of ketone bodies. Subsequent studies transformed understanding of ketone bodies and illustrated the value of challenging the norm and adapting theory to evidence. Key work by Owen, Cahill, and colleagues in the 1960s and 1970s documented that ketone bodies, including BHB, could serve as primary fuels for the brain during starvation, a finding of foundational importance to all subsequent nutritional and supplemental research on BHB.

Traditional and Historical Use Contexts

BHB as an isolated molecule has no traditional ethnobotanical or herbal use; it is an endogenous mammalian metabolite, not a plant-derived ingredient. However, the physiological state of ketosis — in which BHB is the primary circulating fuel — has been deliberately induced throughout history. The therapeutic concept behind the ketogenic diet originates from ancient observations that fasting could significantly alleviate seizures, especially in individuals with epilepsy. In the 1920s, very low carbohydrate/high fat ketogenic diets were introduced in the clinic to treat refractory epilepsy, mimicking the increase in the blood level of ketone bodies including BHB, which were thought to mediate the effect of fasting on seizure events. The deliberate supplementation of exogenous BHB as a dietary ingredient is a late-twentieth and early-twenty-first century development, driven by scientific research rather than traditional use.

3. Endogenous Biochemistry and Ketogenesis

Biosynthetic Pathway

During fasting, free fatty acids from adipocytes are transported to liver mitochondria by carnitine palmitoyltransferase 1 (CPT1). There, β-oxidation produces acetyl-CoA, which, through the sequential action of acetyl-CoA acetyltransferase 1 (ACAT1) and 3-hydroxy-3-methylglutaryl-CoA synthase 2 (HMGCS2), forms HMG-CoA. In hepatic ketogenesis, fatty acid oxidation leads to the production of acetyl-CoA, which, via the sequential enzymatic action of HMGCS2, HMGCL (3-hydroxy-3-methylglutaryl-CoA lyase), and BDH1 (3-hydroxybutyrate dehydrogenase 1), ultimately results in the synthesis of BHB. During fasting, after muscle and liver stores of glycogen are depleted, fatty acids are mobilized from adipocytes and transported to the liver for conversion to ketone bodies. Ketone bodies are then distributed via blood circulation to metabolically active tissues, such as muscle or brain, where they are metabolized into acetyl-CoA and eventually ATP.

Physiological Blood Levels

In healthy humans, the concentration of total circulating ketone bodies exhibits circadian oscillations (0.1–0.2 mM), raises to approximately 1 mM after 24 hours of fasting or prolonged exercise, and even up to 20 mM in pathological states like diabetic ketoacidosis. In humans, serum levels of BHB are usually in the low micromolar range but begin to rise to a few hundred micromolar after 12–16 hours of fasting, reaching 1–2 mM after 2 days of fasting and 6–8 mM with prolonged starvation. It is conventionally understood that when blood ketones rise above 0.5 mmol/L, the heart, brain, and peripheral tissues are using ketone bodies as the primary fuel source — a condition referred to as ketosis.

Tissue Distribution and Utilization

Since ketone bodies possess high permeability to the blood-brain barrier, especially during a low glucose accession period, they become the principal energy source for the brain because glucose supplementation is inadequate. The skeletal muscles adapt to fasting and exercise by utilizing ketone bodies for energy, ensuring their continuing function. Exercise-trained skeletal muscles have an enhanced ability to take up and oxidize ketone bodies during physical activity. An oral D-beta-hydroxybutyrate supplement is rapidly absorbed and metabolized in humans and increases blood ketones to millimolar levels.

4. Key Active Compounds and Mechanisms of Action

BHB has a dual identity: it is simultaneously a major energy substrate and a pleiotropic signaling molecule. Ketone bodies, especially β-HB, derive from fatty acid oxidation and alternatively serve as a fuel source for peripheral tissues including the brain, heart, and skeletal muscle. β-HB is currently considered not solely an energy substrate for maintaining metabolic homeostasis but also acts as a signaling molecule modulating lipolysis, oxidative stress, and neuroprotection. Besides, it serves as an epigenetic regulator in terms of histone methylation, acetylation, and β-hydroxybutyrylation to delay various age-related diseases.

HDAC Inhibition and Epigenetic Regulation

BHB inhibits class I HDACs, leading to increased histone acetylation, which in turn promotes the expression of genes that mitigate oxidative stress, suppress the NLRP3 inflammasome, and regulate GPCRs. BHB has been found to function as a histone deacetylase (HDAC) inhibitor and robustly inhibits HDAC1, HDAC3, and HDAC4 at elevated but physiologically relevant concentrations (IC₅₀ 2.4–5.3 mM). BHB was found as a competitive inhibiting catalytic site, directly inhibiting class I histone deacetylases (HDACs), which were thought to participate in the regulation of gene expression by deacetylating lysine residues on histone and nonhistone proteins, such as NF-κB, TP53, MYC, and MYOD1, and consequently regulates corresponding gene expression.

NLRP3 Inflammasome Suppression

BHB, but neither acetoacetate (AcAc) nor the structurally related short-chain fatty acids butyrate and acetate, suppresses activation of the NLRP3 inflammasome in response to urate crystals, ATP, and lipotoxic fatty acids. Mechanistically, BHB inhibits the NLRP3 inflammasome by preventing K⁺ efflux and reducing ASC oligomerization and speck formation. The inhibitory effects of BHB on NLRP3 are not dependent on chirality or starvation-regulated mechanisms like AMP-activated protein kinase (AMPK), reactive oxygen species (ROS), autophagy, or glycolytic inhibition. Overactivation of the NLRP3 inflammasome is implicated in chronic low-grade inflammation associated with various disease states, including obesity, type 2 diabetes, atherosclerosis, Alzheimer's disease, and Parkinson's disease.

G-Protein-Coupled Receptor Signaling

BHB influences gene expression, lipid metabolism, and inflammation through its inhibition of Class I Histone deacetylases (HDACs) and activation of G-protein-coupled receptors (GPCRs), specifically HCAR2 and FFAR3. BHB activates HCAR2, a seven-transmembrane G-protein coupled receptor of the Gi family, and inhibits the activity of the AC/cAMP/PKA signaling pathway.

Lysine β-Hydroxybutyrylation (Kbhb)

β-OHB is utilized in lysine β-hydroxybutyrylation (Kbhb) of histones, and associates with starvation-responsive genes, effectively coupling ketogenic metabolism with gene expression. Mass spectrometry analysis of the β-hydroxybutyrylome in mouse liver revealed 891 sites of Kbhb within 267 proteins enriched for fatty acid, amino acid, detoxification, and one-carbon metabolic pathways. Kbhb inhibits S-adenosyl-L-homocysteine hydrolase (AHCY), a rate-limiting enzyme of the methionine cycle, in parallel with altered metabolite levels.

Summary of Signaling Properties

BHB's levels rise during periods of low carbohydrate availability. It is used as a metabolic fuel that can be oxidized by metabolic tissues like the brain and heart for ATP production. In addition, BHB is also a signaling molecule that can activate G-protein-coupled receptors, post-translationally modify proteins, or inhibit nuclear histone deacetylases to alter cellular and metabolic processes.

5. Scientific Evidence by Area of Use

5a. Epilepsy and Seizure Control

The ketogenic diet — and by extension, the elevation of BHB — has the strongest and most established clinical evidence in medicine among all uses of ketosis. In GLUT1 deficiency, a pediatric condition characterized by impaired glucose delivery through the blood-brain barrier, the treatment of choice is the ketogenic diet. Ketone bodies, the ketogenic diet, and intermittent fasting have also been shown to be neuroprotective in cell models, animal models, and clinical cases of epilepsy, Alzheimer's, Parkinson's, and Huntington's disease. Ketogenic diets have been used for over 80 years in the treatment of epilepsy. The body of evidence for the ketogenic diet in refractory epilepsy is extensive and supported by systematic reviews. Evidence specifically attributing the anti-seizure effect to BHB rather than other ketogenic diet components remains more mechanistically inferential than definitively established in controlled supplementation trials.

5b. Neurological and Neurodegenerative Diseases

Mechanistic studies suggest that ketone bodies — especially beta-hydroxybutyrate — exert anti-inflammatory, antioxidant, and mitochondrial-stabilizing effects, making them promising therapeutic agents beyond epilepsy.

Alzheimer's Disease (AD): One of the ketone bodies produced as a result of ketogenesis, β-hydroxybutyrate, is known to inhibit NLRP3 inflammasome activation. Testing in the 5XFAD mouse model of AD found that BHB levels are lower in red blood cells and brain parenchyma of AD patients compared with non-AD controls. Furthermore, exogenous BHB administration reduced plaque formation, microgliosis, ASC speck formation, and caspase-1 activation in the 5XFAD mouse model. These findings demonstrate that BHB reduces AD pathology by inhibiting NLRP3 inflammasome activation. These findings are from a preclinical mouse model; human RCT evidence for exogenous BHB supplementation specifically in AD patients is still emerging. There are currently a number of registered clinical trials investigating exogenous ketones in the form of medium-chain triglycerides, ketone salts, or ketone esters in MCI or AD.

Parkinson's Disease: The main ketone body, beta-hydroxybutyrate, has the potential to reduce the symptoms of Parkinson's disease, such as loss of dopaminergic neurons and mitochondrial insufficiency. Evidence here is primarily from cell-based and animal studies; robust human RCT data are limited.

General Neuroprotection: Several studies have shown neuroprotective properties of BHB and acetoacetate in experimental models of neurodegenerative diseases of the brain, in particular Parkinson's disease or Alzheimer's disease, but also in traumatic brain injury or cerebral hypoxia. The overall state of this field is that the preclinical evidence is substantial and mechanistically plausible, but large-scale human RCT evidence specifically for BHB supplementation is still preliminary and ongoing.

5c. Cardiovascular System and Heart Failure

Heart failure triggers a shift in myocardial metabolic substrate utilization, favoring the ketone body 3-hydroxybutyrate as an energy source. It has been demonstrated that the acute infusion and elevation of BHB increases cardiac output in patients with heart failure with reduced ejection fraction (HFrEF).

A randomized, controlled, double-blind trial published in Circulation (2024) enrolled 26 participants with HFrEF and tested 14-day oral ketone ester (KE) treatment. Heart failure triggers a shift in myocardial metabolic substrate utilization, favoring the ketone body 3-hydroxybutyrate as energy source. The investigators hypothesized that 14-day treatment with ketone ester would improve resting and exercise hemodynamics and exercise capacity in patients with heart failure with reduced ejection fraction. This small but rigorously designed study is indicative of active clinical translation; the size of the trial necessitates confirmation in larger studies.

In preclinical animal models, ketone ester (KE) treatment alleviated TAC-induced cardiomyocyte hypertrophy and reduced the TAC-induced elevated cardiac periostin, a marker of activated fibroblasts. Cardiac fibrosis was also significantly reduced with KE treatment in TAC mice. Acute BHB infusion significantly increased the cardiac output of mice with HF, providing further support that ketone therapy can be used to treat HF.

An inducible compound heterozygote knockout of HDAC1 and HDAC2 suppresses one translatable age-related phenotype, cardiac hypertrophy, as do HDAC inhibitors. HDAC inhibitors ameliorate cardiac dysfunction in mouse diabetes models and prevent maladaptive cardiac remodeling. The mechanism for the effect on cardiac hypertrophy appears to be inhibition of HDACs that suppress the activity of a mechanistic mTOR complex.

5d. Athletic Performance and Exercise Metabolism

As an alternative to a very high fat ketogenic diet, ketone precursors for oral intake are being developed to achieve ketosis without the need for dietary carbohydrate restriction. An oral D-beta-hydroxybutyrate supplement is rapidly absorbed and metabolized in humans and increases blood ketones to millimolar levels. At the same dose, D-BHB is significantly more ketogenic and provides fewer calories than a racemic mixture of BHB or medium chain triglyceride.

One randomized, double-blind, crossover study with 13 recreational male distance runners (aged 24.8 ± 9.6 years, VO₂max 60.1 ± 5.4 ml/kg/min) evaluated dose-response effects of a novel BHB salt + MCT formulation. Subjects consumed either one (22.1 g) or two (44.2 g) servings of the ketone supplement or a flavor-matched placebo 60 minutes prior to performing a 5-km running time trial. The ketone supplement significantly increased R-βHB, with more potent and prolonged elevations in the higher dose, illustrating an administrative and dosing effect. Gaseous exchange, respiration, HR, affect, RPE, and exercise performance were unaltered with ketone supplement administration. However, clear responders and non-responders were indicated. The higher dose significantly augmented cognitive function in pre-exercise conditions, while exercise increased cognitive performance for the lower dose and placebo to pre-exercise levels of the higher dose. The novel βHB + MCT formulation had a dosing effect on R-βHB and cognitive performance, but did not influence gaseous exchange, respiration, HR, affect, RPE, and exercise performance.

Exogenous ketone supplementation acutely elevates circulating beta-hydroxybutyrate (R-BHB), but the impact of chronic repeated dosing on exercise performance, cognition, mood, and cardiometabolic health remains unclear. A 2026 RCT (31 days, 18 recreational runners, thrice-daily ketone monoester at 90 g/day) evaluated the effects of 31 days of thrice-daily KME supplementation (90 g/day; high-dose) on exercise performance, executive function, mood, metabolism, body composition, blood pressure, and tolerability in recreational runners. Overall, the evidence for exogenous BHB improving athletic performance — beyond acute metabolic effects — is mixed and does not yet support a clear, consistent ergogenic benefit.

5e. Cognitive Function

Since ketone bodies possess high permeability to the blood-brain barrier, they become the principal energy source for the brain when glucose supply is inadequate. BHB's role as a direct brain fuel underpins considerable interest in cognitive applications. Nutritional ketosis (0.5–6.0 mM beta-hydroxybutyrate) has been extensively investigated for potential effects on cognition. Preliminary evidence from small trials and mechanistic studies is encouraging, but the degree of cognitive benefit in healthy populations is not yet established by large-scale RCTs.

5f. Metabolism, Obesity, and Type 2 Diabetes

Emerging evidence, mostly from cell and animal models of disease, supports a role for ketosis in general, and BHB in particular, in reducing NLRP3 inflammasome activation to improve chronic inflammation. As a result, interventions that induce ketosis, such as fasting, intermittent fasting, time-restricted feeding, ketogenic diets, and exogenous ketone supplementation, have garnered increasing interest for their therapeutic potential. Much of the available evidence on metabolic outcomes is derived from studies of the ketogenic dietary pattern rather than isolated BHB supplementation; the independent contribution of exogenous BHB to metabolic outcomes in clinical trials remains an area of active investigation.

5g. Inflammation and Aging

The signaling functions of BHB broadly link the outside environment to epigenetic gene regulation and cellular function, and their actions may be relevant to a variety of human diseases as well as human aging. Traditionally recognized as an alternative energy substrate during fasting, caloric restriction, and starvation, BHB has gained attention for its diverse signaling roles in various physiological processes. Research is exploring the emerging therapeutic potential of BHB in the context of sarcopenia, metabolic disorders, and neurodegenerative diseases. Evidence in this domain currently derives predominantly from animal and in vitro research; controlled human intervention data are limited.

5h. Kidney Disease

Several studies suggest that dietary BHB supplementation delays the progression of chronic kidney disease (CKD) by suppressing inflammation and fibrosis. A study in Alport syndrome mice (Col4a3-deficient mice) tested the BHB precursor 1,3-butanediol in addition to inhibitors of the renin-angiotensin system and sodium-glucose transporter 2. The results in mice suggest that BHB supplementation improves GFR in Alport syndrome by suppressing inflammation and fibrosis. However, the effects did not lead to a significant increase in lifespan. This evidence is currently preclinical.

6. Body Systems Associated with BHB

Nervous system: Primary alternative fuel for the brain during glucose restriction; implicated in epilepsy management, neuroprotection, and cognitive function.
Cardiovascular system: Alternative myocardial energy substrate; investigated in heart failure and cardiac remodeling.
Metabolic/endocrine system: Regulation of insulin signaling, lipolysis, adipose metabolism, and inflammation.
Musculoskeletal system: Substrate for exercising muscle; potential role in sarcopenia and muscle preservation.
Immune system: Modulation of the NLRP3 inflammasome and macrophage polarization.
Renal system: Renal tubules predominantly utilize lipids, not glucose, as their primary energy source. As with the heart, the kidneys can adapt to using ketone bodies.
Epigenetic/genomic: Histone modification via Kbhb and HDAC inhibition; gene expression regulation linked to starvation-responsive pathways.

7. Dosage Forms and Dosages Reported in Studies

The following dosages are drawn directly from cited research sources. They describe doses used in specific studies and do not represent clinical recommendations.

A study used two 15 g D-BHB doses (one at −75 min and the other at −30 min prior to infusion) in its supplementation protocol.
In a crossover study, participants consumed either one (KS1: 22.1 g) or two (KS2: 44.2 g) servings of a ketone supplement (βHB + MCT) 60 minutes prior to a 5-km running time trial.
One 31-day RCT evaluated thrice-daily ketone monoester supplementation at 90 g/day total (30 g per dose) versus an isocaloric, flavor-matched placebo (n = 9 per group) in recreational runners.
One investigation examined responses to single doses of the KME at lower doses (5 and 10 g) and compared those with a ketone ester + R-βHB salt mixture (KMES) at 5 and 10 g doses.
The ketone monoester (R)-3-hydroxybutyl (R)-3-hydroxybutyrate effectively elevated blood ketone levels in healthy volunteers, reaching maximum plasma concentrations of 3.30 mM for β-hydroxybutyrate within 1–2 hours after ingestion.
Studies show that the BHB monoester rapidly raises blood ketone levels, peaking at about one hour and maintaining ketosis for three to four hours, depending on the dose.
Free D-BHB: A safety and tolerability study evaluated orally administered free D-BHB in a gender and age-balanced sample of 24 asymptomatic and overtly healthy adults. The study tracked 720 individual doses and characterized adverse event frequency.

8. Safety Considerations and Drug/Nutrient Interactions

General Tolerability

The most reported secondary effects in a clinical safety study (19 out of 720 doses, or 2.6%) were gastrointestinal discomfort; headache (7/720 or 1%) and loss of appetite (7/720 or 1%) were also noted. The rest of the reported secondary symptoms were reported less than 1% of the time.

Racemic βHB has been used clinically in patients and consumers for years, and no serious adverse events from βHB supplement ingestion have been reported in the CAERS open-FDA database, even with over 1 million estimated servings consumed annually.

Gastrointestinal Effects

High doses of KME have been associated with mild gastrointestinal distress. The ketone monoester was generally well-tolerated over a 5-day period, although some gastrointestinal side effects were noted at higher doses. Both exogenous ketone salts and esters may cause infrequent mild gastrointestinal effects.

Mineral Load from BHB Salts

Being salt-free, free D-BHB could have a broader clinical reach than previous ketone supplements — for example, in patients with mineral load restrictions such as those living with heart failure or chronic kidney disease. BHB mineral salts carry electrolytes; repeated use changes mineral intake, which matters if one has kidney disease or takes certain medications. The high sodium content of BHB salts (up to 1,000 mg or more per serving) may be unsuitable for people with certain health conditions, such as uncontrolled hypertension.

Ketone Ester-Specific Considerations

Ketone esters carry a different concern: they contain an alcohol precursor (1,3-butanediol) that the liver must process. Downsides of ketone esters include cost, unpleasant taste, and a higher risk of gastrointestinal upset for some people.

Enantiomeric Considerations

One consideration with racemic BHB supplements is the potential differences in metabolism of S-βHB and R-βHB, although existing data on this is still limited. Based on previous studies, S-βHB and R-βHB from racemic mixtures are naturally metabolized in rats and humans, but S-βHB remains elevated in blood longer.

Gaps in Long-Term Safety Data

Short-term animal and human studies using these products suggest significant potential for primary or secondary prevention of a number of chronic disease conditions. However, a number of questions need to be addressed by the field for optimal use in humans, including variable responses among available exogenous ketones at different dosages, frequency of dosing, and their tolerability, acceptability, and efficacy in long-term clinical trials.

References

Health Conditions

Health conditions that Beta-hydroxybutyrate may help support.

No conditions available.

Body Systems

Body systems that Beta-hydroxybutyrate may help support.

No body systems available.